Skip to main content
SpringerLink
Log in

Fluorescence Cytoscopy

  • Chapter
  • First Online:
Bladder Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 1058 Accesses

Abstract

Conventional diagnostic strategies for bladder cancer have consisted of white light cystoscopy and urine markers. It is recognized that white light cystoscopy can fail to detect carcinoma in situ (CIS). Furthermore, recent experiences with fluorescence cystoscopy demonstrate that white light cystoscopy can fail to detect papillary tumors as well. Several fluorescence agents have been used for photodynamic detection of bladder cancer, including 5-aminolevulinic acid, hexylester aminolevulinate, and hypericin. These novel agents can be applied intravesically from one to several hours prior to cystoscopy with no reported systemic toxicity, resulting in improved bladder cancer detection rates, particularly for CIS.

Recent phase III trials have demonstrated that transurethral resection of bladder tumors using fluorescence reduces short-term recurrence rates. Fluorescence cystoscopy is starting to play an increasing role in our diagnostic and therapeutic armamentarium for nonmuscle invasive bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54(1):8–29.

    Article  PubMed  Google Scholar 

  2. SEER cancer statistics 2005 Accessed 2005, at http://seer.cancer.goc/statistics/; 2005.

  3. Kurth KH. Natural history and prognosis of untreated and treated superficial bladder cancer. Isis Medical Media; 1997.

    Google Scholar 

  4. Spiess PE, Grossman HB. Fluorescence cystoscopy: is it ready for use in routine clinical practice? Curr Opin Urol 2006;16:372–6.

    Article  PubMed  Google Scholar 

  5. Zaak D, Karl A, Knuchel R, et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int 2005;96(2):217–22.

    Article  PubMed  Google Scholar 

  6. Joudi FN, Konety BR. Fluorescence cystoscopy and bladder surveillance. Curr Opin Urol 2004;14(5):265–70.

    Article  PubMed  Google Scholar 

  7. Jocham D, Baumgartner R, Fuchs N, Lenz H, Stepp H, Unsold E. [Fluorescence diagnosis of porphyrin-marked urothelial tumors. Status of experimental development]. Urologe A 1989;28(2):59–64.

    CAS  PubMed  Google Scholar 

  8. Zaak D, Kriegmair M, Stepp H, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 2001;57(4):690–4.

    Article  CAS  PubMed  Google Scholar 

  9. Filbeck T, Wimmershoff MB, Pichlmeier U, et al. No generalized skin phototoxicity after intravesical application of 5-aminolevulinic acid for fluorescence diagnosis of superficial bladder cancer. Urol Int 2000;64(3):126–8.

    Article  CAS  PubMed  Google Scholar 

  10. Popken G, Schultze-Seemann W, Seiler KU, et al Intravesical administration of 5-aminolevulinic acid (5-ALA). Safety and pharmacokinetics of 5-ALA and its metabolite protoporphyrin IX. Eur J Clin Pharmacol 2000;56(3):241–6.

    Article  CAS  PubMed  Google Scholar 

  11. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer–a multicenter study. J Urol 2003;170(1):226–9.

    Article  PubMed  Google Scholar 

  12. Zaak D, Hungerhuber E, Schneede P, et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 2002;95(6):1234–8.

    Article  PubMed  Google Scholar 

  13. Grimbergen MC, van Swol CF, Jonges TG, Boon TA, van Moorselaar RJ. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol 2003;44(1):51–6.

    Article  CAS  PubMed  Google Scholar 

  14. Kriegmair M, Baumgartner R, Knuchel R, et al. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996;155(1):105–9.

    Article  CAS  PubMed  Google Scholar 

  15. Schmidbauer J, Witjes F, Schmeller N, et al. Improved detection of urothelial carcinoma in situ with ­hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171(1):135–8.

    Article  PubMed  Google Scholar 

  16. D'Hallewin MA, Kamuhabwa AR, Roskams T, et al. Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU Int 2002;89(7):760–3.

    Article  PubMed  Google Scholar 

  17. Sim HG, Lau WK, Olivo M, et al Is photodynamic diagnosis using hypericin better than white-light cystoscopy for detecting superficial bladder carcinoma? BJU Int 2005;95(9):1215–8.

    Article  PubMed  Google Scholar 

  18. Koenig F, McGovern FJ. Fluorescence detection of bladder carcinoma. Urology 1997;50(5):778–9.

    Article  CAS  PubMed  Google Scholar 

  19. Lange N, Jichlinski P, Zellweger M, et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer 1999;80(1–2):185–93.

    Article  CAS  PubMed  Google Scholar 

  20. Fotinos N, Campo MA, Popowycz F, et al 5-Aminolevulinic Acid Derivatives in Photomedicine: Basics, Application and Perspectives. Photochem Photobiol 2006;82(4):994–1015.

    Article  CAS  PubMed  Google Scholar 

  21. Hexyl aminolevulinate: 5-ALA, hexylester, 5-ALA hexylesther, aminolevulinic acid hexyl ester, hexaminolevulinate, hexyl 5-aminolevulinate, P 1206. Drugs R D 2005;6(4):235–8.

    Google Scholar 

  22. D'Hallewin MA, De Witte PA, Waelkens E, et al. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. J Urol 2000;164(2):349–51.

    Article  PubMed  Google Scholar 

  23. Lavie G, Mazur Y, Lavie D, Meruelo D. The chemical and biological properties of hypericin–a compound with a broad spectrum of biological activities. Med Res Rev 1995;15(2):111–9.

    Article  CAS  PubMed  Google Scholar 

  24. Yamazaki T, Ohta N, Yamazaki I, Song PS. Excited state properties of hypericin:electronic spectra and fluorescence decay kinetics. J Phys Chem 1993;97:7870–5.

    Article  CAS  Google Scholar 

  25. Loidl W, Schmidbauer J, Susani M, Marberger M. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol 2005;47(3):323–6.

    Article  CAS  PubMed  Google Scholar 

  26. Witjes JA, Moonen PM, van der Heijden AG. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study. Eur Urol 2005;47(3):319–22.

    Article  PubMed  Google Scholar 

  27. Zlotta A. Fluorescence cystoscopy: is flexible scope as effective as rigid? Eur Urol 2005;47(3):318.

    Article  PubMed  Google Scholar 

  28. Jichlinski P, Leisinger HJ. Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist! Urol Int 2005;74(2):97–101.

    Article  PubMed  Google Scholar 

  29. Koenig F, McGovern FJ, Larne R, et al. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int 1999;83(1):129–35.

    Article  CAS  PubMed  Google Scholar 

  30. Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005;174(3):862–6.

    Article  PubMed  Google Scholar 

  31. Grossman HB, Gomella LG, Fradet Y, et al. The use of Hexvix and fluorescence cystoscopy as an adjunct in the diagnosis of stage Ta/T1 urothelial cancer in the urinary bladder (abstract 263). J Urol 2004;171:69.

    Google Scholar 

  32. Durek C, Wagner S, Zeylemaker B, et al The significance of hexyl 5-aminolevulinate hydrochloride based fluorescence cystoscopy in treatment decisions- results of a prospective phase 3 multicenter study. In: European Association of Urology Annual Meeting,Vienna. Amsterdam: Elsevier BV; 2004.

    Google Scholar 

  33. Filbeck T, Pichlmeier U, Knuechel R, et al. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 2002;168(1):67–71.

    Article  PubMed  Google Scholar 

  34. Babjuk M, Soukup V, Petrik R, et al. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005;96(6):798–802.

    Article  CAS  PubMed  Google Scholar 

  35. Daniltchenko DI, Riedl CR, Sachs MD, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005;174(6):2129–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, MD Anderson Cancer Center, Houston, TX, USA

    Philippe E. Spiess

  2. Department of Urology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    H. Barton Grossman

Authors
  1. Philippe E. Spiess
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Barton Grossman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. Urology, University of Michigan Health System, E. Medical Center Dr. 1500 , Ann Arbor, 48109-0252, U.S.A.

    Cheryl T. Lee

  2. Dept. Urology, University of Michigan Health System, E. Medical Center Dr. 1500 , Ann Arbor, 48109-0252, U.S.A.

    David P. Wood

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Spiess, P.E., Grossman, H.B. (2009). Fluorescence Cytoscopy. In: Lee, C., Wood, D. (eds) Bladder Cancer. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-59745-417-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-417-9_2

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-988-8

  • Online ISBN: 978-1-59745-417-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation